T1	Treatment 211 219	(TGF-Î²)
T2	Treatment 346 347	.
T3	Treatment 348 381	TGF-beta receptor type-2 (TGFBR2)
T4	Treatment 608 628	randomised tamoxifen
T5	Treatment 696 711	examined TGFBR2
T6	Treatment 771 792	target SMAD2 (pSMAD2)
T7	Treatment 801 840	in cancer-associated fibroblasts (CAFs)
T8	Treatment 1753 1764	transfected
T9	Treatment 1787 1791	with
